Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.64 |
| ▸ | CTSK | P43235 | 5/20 | 0.64 |
| ▸ | CTSB | P07858 | 3/20 | 0.64 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30346429 | 1.00 | CTSS (0.64) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL21583861 | 1.00 | CTSS (0.64) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL4838552 | 0.87 | CTSS (0.64) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL23900516 | 0.85 | JAK2 (0.50) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2141200 | 0.85 | CTSS (0.48) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2141206 | 0.85 | CTSS (0.48) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL4859989 | 0.85 | CTSS (0.61) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL20905314 | 0.85 | CTSS (0.71) | CTSSCTSKCTSBCTSLAAK1 | |
| SCHEMBL4859984 | 0.85 | CTSS (0.61) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2333358 | 0.85 | CTSS (0.74) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117813288-A | Arylamino derivative estrogen receptor modulator and use thereof | 西藏海思科制药有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-115594673-A | Estrogen receptor modulators and uses thereof | 扬子江药业集团南京海陵药业有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-9783500-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783500-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-7504403-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1716150-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1716150-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005070932-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MUSK, MAPT | CTSS 255/4885CTSK 611/4885CTSB 776/4885 |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NOS2, NOS3, NOS1 | CTSS 2769/4885CTSK 2948/4885CTSB 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.